🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.2750
-0.0143 (-4.94%)
At close: Nov 19, 2026, 4:00 PM EST
0.2870
+0.0120 (4.36%)
After-hours: Nov 19, 2026, 7:30 PM EST

Mereo BioPharma Group Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.80.5-10-49.37
Revenue Growth
60.00%-----
Cost of Revenue
-0.13-2.57-1.1524.25
Gross Profit
0.80.37-7.431.1525.13
Selling, General & Admin
18.3723.0126.4318.4226.1121.57
Research & Development
12.0515.9219.2816.1427.7431.9
Other Operating Expenses
--0.3----
Operating Expenses
30.4238.6245.7234.5653.8453.47
Operating Income
-29.62-38.26-45.72-27.14-52.7-28.35
Interest Expense
-0.07-0.26-1.37-2.88-4.18-5.11
Interest & Investment Income
1.272.173.042.130.840
Currency Exchange Gain (Loss)
1.17-6.341.21-2.352.72-1.29
Other Non Operating Income (Expenses)
0.320.81-0.420.2410.3753.88
EBT Excluding Unusual Items
-26.94-41.88-43.25-30-42.9419.13
Gain (Loss) on Sale of Assets
-----0.15
Pretax Income
-26.94-41.88-43.25-30-42.9419.28
Income Tax Expense
----0.53-0.722.05
Net Income
-26.94-41.88-43.25-29.47-42.2217.23
Net Income to Common
-26.94-41.88-43.25-29.47-42.2217.23
Net Income Growth
------
Shares Outstanding (Basic)
161159148132121106
Shares Outstanding (Diluted)
161159148132121111
Shares Change
1.49%7.77%12.16%9.33%8.63%63.82%
EPS (Basic)
-0.17-0.26-0.29-0.22-0.350.16
EPS (Diluted)
-0.17-0.26-0.29-0.22-0.35-0.31
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-22.09-30.99-32.83-21.13-48.83-7.82
Free Cash Flow Per Share
-0.14-0.19-0.22-0.16-0.41-0.07
Gross Margin
100.00%73.40%-74.26%-50.89%
Operating Margin
-3702.50%-7651.40%--271.36%--57.42%
Profit Margin
-3367.25%-8375.60%--294.66%-34.90%
Free Cash Flow Margin
-2761.00%-6198.20%--211.32%--15.83%
EBITDA
-28.67-37.64-45.13-26.57-52.52-28.25
EBITDA Margin
----265.70%--57.22%
D&A For EBITDA
0.960.620.580.570.180.1
EBIT
-29.62-38.26-45.72-27.14-52.7-28.35
EBIT Margin
----271.36%--57.42%
Effective Tax Rate
-----10.64%
SEC Filings: 10-K · 10-Q